Results 31 to 40 of about 40,867 (262)
Effect of risedronate on bone loss at discontinuation of denosumab
Bone Reports, 2020 Purpose: The occurrence of multiple vertebral fractures was reported after denosumab discontinuation. The use of bisphosphonates following denosumab has been suggested to prevent this bone loss.
Michel Laroche +4 more
doaj +1 more source
Bone, 2023 INTRODUCTION Increased RANKL expression is observed in the bone tissue of fibrous dysplasia of bone/McCune-Albright syndrome (FD/MAS). In one animal model of FD/MAS, the inhibition of RANKL reduced tumor volume.
M. Trojani +8 more
semanticscholar +1 more source
Medication-related osteonecrosis of the jaw: clinical and practical guidelines [PDF]
, 2016 Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse drug reaction, consisting of progressive bone destruction in the maxillofacial region of patients.
Allen +42 more
core +2 more sources
Denosumab treatment in patients with different courses of osteoporosis
Остеопороз и остеопатии, 2017 We present three clinical cases of successful osteoporosis treatment with denosumab in patients with different courses of osteoporosis: postmenopausal with bisphosphonates ineffectiveness, osteoporosis of mixed etiology in patient on thyroid stimulating ...
Liudmila Ya. Rozhinskaya +4 more
doaj +1 more source
Journal of Clinical Endocrinology and Metabolism, 2020 CONTEXT Denosumab discontinuation is characterized by an increase in bone turnover overriding pre-treatment status, a rapid bone loss in the majority and multiple vertebral fractures (VFx) in some patients.
E. Tsourdi +16 more
semanticscholar +1 more source
SAT-512 Severe Hypocalcemia Presenting as Status Epilepticus after Denosumab Use in Metastatic Prostate Cancer [PDF]
, 2019 Introduction: Denosumab decreases the incidence of skeletal-related events in patients with metastatic bone disease and is used routinely as part of the therapeutic strategy for various cancers.
Aziz, Ammara, Saeed, Zeb
core +1 more source
Frontiers in Endocrinology, 2020 Denosumab is a potent osteoclast inhibitor targeted to prevent osteoporotic bone loss and thereby reduce fractures in the aging population. Recently, an elevated risk of rebound fractures following denosumab discontinuation was identified, unless ...
Katharina Jähn-Rickert +7 more
doaj +1 more source
Denosumab in pediatric bone disorders and the role of RANKL blockade: a narrative review
Translational Pediatrics, 2023 Background and Objective Denosumab is a valuable and safe therapy for skeletal disorders in adults and has received regulatory approval to treat osteoporosis and bone metastases.
Daoxi Wang +6 more
semanticscholar +1 more source
Persistence with Denosumab in Male Osteoporosis Patients: A Real-World, Non-Interventional Multicenter Study [PDF]
Endocrinology and Metabolism, 2023 Background Persistence with denosumab in male patients has not been adequately investigated, although poor denosumab persistence is associated with a significant risk of rebound vertebral fractures.
Chaiho Jeong +11 more
doaj +1 more source
Journal of Clinical Endocrinology and Metabolism, 2023 Context Denosumab is an effective treatment for many receptor activator of nuclear factor kappa-B ligand (RANKL)-mediated disorders but there are potential safety considerations and limited data to guide its use in children and adolescents.
Joel A. Vanderniet +9 more
semanticscholar +1 more source